This article has been cited by other articles in PMC.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (547K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
Auf G, Ghanadian R. Analysis of androgen receptors in the human prostate by isoelectric focussing in polyacrylamide gel. J Steroid Biochem. 1981 Dec;14(12):1261–1267.[PubMed]
Blackard CE. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep. 1975 Jan-Feb;59(1):225–227.[PubMed]
Concolino G, Marocchi A, Margiotta G, Conti C, Di Silverio F, Tenaglia R, Ferraro F, Bracci U. Steroid receptors and hormone responsiveness of human prostatic carcinoma. Prostate. 1982;3(5):475–482.[PubMed]
Coune A, Smith P. Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Cancer Chemother Rep. 1975 Jan-Feb;59(1):209–213.[PubMed]
Denis L, Declercq G. Anti-estrogens in the treatment of prostatic cancer. Acta Urol Belg. 1980 Jan;48(1):106–109.[PubMed]
Geller J, Albert J, Yen SS. Treatment of advanced cancer of prostate with megestrol acetate. Urology. 1978 Nov;12(5):537–541.[PubMed]
Geller J, Albert J, Yen SS, Geller S, Loza D. Medical castration with megestrol acetate and minidose of diethylstilbestrol. Urology. 1981 Apr;17(4 Suppl):27–33.[PubMed]
Ghanadian R, Auf G, Williams G, Davis A, Richards B. Predicting the response of prostatic carcinoma to endocrine therapy. Lancet. 1981 Dec 19;2(8260-61):1418–1418.[PubMed]
Huggins C, Scott WW. Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg. 1945 Dec;122(6):1031–1041.[PubMed]
Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology. 1976 Sep;8(3):231–233.[PubMed]
Kerle D, Williams G, Ware H, Bloom SR. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Br Med J (Clin Res Ed) 1984 Aug 25;289(6443):468–469.[PMC free article][PubMed]
Pontes JE, Karr JP, Kirdani RY, Murphy GP, Sandberg AA. Estrogen receptors and clinical correlations with human prostatic disease. Urology. 1982 Apr;19(4):399–403.[PubMed]
Reiner WG, Scott WW, Eggleston JC, Walsh PC. Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol. 1979 Aug;122(2):183–184.[PubMed]
Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971 Apr 16;43(2):393–399.[PubMed]
Trachtenberg J. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol. 1983 Jun;129(6):1149–1152.[PubMed]
Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984 Aug 25;2(8400):433–435.[PubMed]
Trachtenberg J, Walsh PC. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol. 1982 Mar;127(3):466–471.[PubMed]
Walsh PC. Physiologic basis for hormonal theapy in carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):125–140.[PubMed]
Williams G, Kerle D, Griffin S, Dunlop H, Bloom SR. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system. Br Med J (Clin Res Ed) 1984 Dec 8;289(6458):1580–1581.[PMC free article][PubMed]
Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press